Tetrandrine Represses Inflammation and Attenuates Osteoarthritis by Selective Inhibition of COX-2

Abstract

Objective

There is a lack of effective and long-term safe drugs for the treatment of osteoarthritis (OA). Tetrandrine (Tet) has been approved and used to treat rheumatoid arthritis for several decades, but its effect on OA has not been investigated. Herein, we explored the effect of Tet on OA and its underlying mechanism.

Methods

OA was induced using destabilization of the medial meniscus (DMM) in C57BL/6J mice. The animals were randomly divided into sham, DMM, Tet, celecoxib (CXB), and indomethacin (INDO) groups. Each group was given solvent or corresponding drugs by gavage for 7 weeks after convalescence. Pathological staining, OARSI scores, micro-computed tomography and behavior tests were performed to evaluate the effects of Tet.

Results

Tet remarkably alleviated cartilage injury in the knee joint, limited bone remodeling in the subchondral bone, and delayed progression of OA. Tet also significantly relieved joint pain and maintained function. Further mechanistic studies revealed that Tet lowered inflammatory cytokine levels and selectively suppressed gene and protein expression of cyclooxygenase (COX)-2 but not COX-1 (P<0.01). Tet also reduced the production of prostaglandin E2 without damaging the gastric mucosa.

Conclusion

We found that Tet could selectively inhibit COX-2 gene expression and decrease cytokine levels in mice, thus reducing inflammation and improving OA without obvious gastric adverse events. These results provide a scientific basis for the clinical application of Tet in the treatment of OA.

Keywords

tetrandrine / osteoarthritis / cyclooxygenase-2 / gastric mucosa

References

[1] KatzJN, ArantKR, LoeserRF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA, 2021, 325(6): 568-578

[2] EmeryCA, WhittakerJL, MahmoudianA, et al.. Establishing outcome measures in early knee osteoarthritis. Nat Rev Rheumatol, 2019, 15(7): 438-448

[3] HunterDJ, Bierma-ZeinstraS. Osteoarthritis. Lancet, 2019, 393(10182): 1745-1759

[4] WangB, XingD, DongS, et al.. Prevalence and disease burden of knee osteoarthritis in China: a systematic review. Zhongguo Xunzheng Yixue Zazhi (Chinese), 2018, 18(02): 134-142

[5] SchjerningAM, McGettiganP, GislasonG. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol, 2020, 17(9): 574-584

[6] BinduS, MazumderS, BandyopadhyayU. Nonsteroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol, 2020, 180: 114147

[7] PelletierJ-P, Martel-PelletierJ, RannouF, et al.. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum, 2016, 45(4): S22-S27

[8] XuW, ChenS, WangX, et al.. Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases. Pharmacol Ther, 2021, 217: 107659

[9] KongX, ZuoH, LiY. Pharmacological effects and clinical application of tetrandrine: research advances. J Int Pharm Res, 2020, 47(07): 496-501

[10] LuanF, HeX, ZengN. Tetrandrine: a review of its anticancer potentials, clinical settings, pharmacokinetics and drug delivery systems. J Pharm Pharmacol, 2020, 72(11): 1491-1512

[11] SuW, LiangY, MengZ, et al.. Inhalation of Tetrandrine-hydroxypropyl-β-cyclodextrin Inclusion Complexes for Pulmonary Fibrosis Treatment. Mol Pharm, 2020, 17(5): 1596-1607

[12] LiuZ, LiY, GuoF, et al.. Tetrandrine Inhibits Titanium Particle-Induced Inflammatory Osteolysis through the Nuclear Factor-κB Pathway. Mediators Inflamm, 2020, 2020: 1926947

[13] LiX, WuZ, HeB, et al.. Tetrandrine alleviates symptoms of rheumatoid arthritis in rats by regulating the expression of cyclooxygenase-2 and inflammatory factors. Exp Ther Med, 2018, 16(3): 2670-2676

[14] WangT, HeC. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev, 2018, 44: 38-50

[15] RobinsonWH, LepusCM, WangQ, et al.. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol, 2016, 12(10): 580-592

[16] TakeuchiK, AmagaseK. Roles of Cyclooxygenase, Prostaglandin E2 and EP Receptors in Mucosal Protection and Ulcer Healing in the Gastrointestinal Tract. Curr Pharm Des, 2018, 24(18): 2002-2011

[17] YeomansND, GrahamDY, HusniME, et al.. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther, 2018, 47(11): 1453-1463

[18] JacksonLM, WuKC, MahidaYR, et al.. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut, 2000, 47(6): 762-770

[19] AguilarPV, BedouiY, Septembre-MalaterreA, et al.. Robust COX-2-mediated prostaglandin response may drive arthralgia and bone destruction in patients with chronic inflammation post-chikungunya. PLoS Negl Trop Dis, 2021, 15(2): e0009115

[20] ShimYK, KimN. Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease. Korean J Gastroenterol, 2016, 67(6): 300-312

[21] AshrafS, MappPI, BurstonJ, et al.. Augmented pain behavioural responses to intra-articular injection of nerve growth factor in two animal models of osteoarthritis. Ann Rheum Dis, 2014, 73(9): 1710-1718

[22] NakataK, HanaiT, TakeY, et al.. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage, 2018, 26(10): 1263-1273

[23] ZhaoY, LiuB, LiuCJ. Establishment of a surgically-induced model in mice to investigate the protective role of progranulin in osteoarthritis. J Vis Exp, 2014, 84: e50924

[24] YuanX, TongB, DouY, et al.. Tetrandrine ameliorates collagen-induced arthritis in mice by restoring the balance between Th17 and Treg cells via the aryl hydrocarbon receptor. Biochem Pharmacol, 2016, 101: 87-99

[25] XiangHC, LinLX, HuXF, et al.. AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression. J Neuroinflammation, 2019, 16(1): 34

[26] KhanJ, AliG, KhanR, et al.. Attenuation of vincristine-induced neuropathy by synthetic cyclohexenone-functionalized derivative in mice model. Neurol Sci, 2019, 40(9): 1799-1811

[27] WangH, LiX, ZhangsunD, et al.. The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain. Mar Drugs, 2019, 17(5): 265

[28] GlassonSS, ChambersMG, Van Den BergWB, et al.. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage, 2010, 18(Suppl3): S17-23

[29] GhouriA, ConaghanPG. Update on novel pharmacological therapies for osteoarthritis. Ther Adv Musculoskelet Dis, 2019, 11: 1759720X19864492

[30] JiaY, TaoY, LvC, et al.. Tetrandrine enhances the ubiquitination and degradation of Syk through an AhR-c-src-c-Cbl pathway and consequently inhibits osteoclastogenesis and bone destruction in arthritis. Cell Death Dis, 2019, 10(2): 38

[31] ZhaoH, LuoF, LiH, et al.. Antinociceptive effect of tetrandrine on LPS-induced hyperalgesia via the inhibition of IKKbeta phosphorylation and the COX-2/PGE(2) pathway in mice. PLoS One, 2014, 9(4): e94586

[32] Martel-PelletierJ, BarrAJ, CicuttiniFM, et al.. Osteoarthritis. Nat Rev Dis Primers, 2016, 2: 16072

[33] ChowYY, ChinKY. The Role of Inflammation in the Pathogenesis of Osteoarthritis. Mediators Inflamm, 2020, 2020: 8293921

[34] JiaZ, ZhangY, DingG, et al.. Role of COX-2/mPGES-1/prostaglandin E2 cascade in kidney injury. Mediators Inflamm, 2015, 2015: 147894

[35] TuM, YangM, YuN, et al.. Inhibition of cyclooxygenase-2 activity in subchondral bone modifies a subtype of osteoarthritis. Bone Res, 2019, 7: 29